Weight Loss

In adults with HF with preserved ejection fraction and obesity, semaglutide 2.4 mg significantly improved HF-related symptoms and physical limitations and was associated with greater weight loss compared with placebo, researchers reported.

Adults with overweight or obesity had a 10% annual probability of achieving 5% or greater weight loss, according to study data published in JAMA Network Open.

A new generation of obesity drugs is changing the treatment landscape for patients and providers, with options that can lead to weight loss unheard of just a few years ago.

A 10-year intensive lifestyle intervention designed for weight loss in those with type 2 diabetes and overweight/obesity was tied to significantly higher employment levels compared with diabetes education alone, according to researchers.

Although telephone-based cognitive behavioral therapy did not change short-term weight outcomes in patients 1 year after bariatric surgery, it did improve disordered eating and psychological distress, researchers reported.

Adults with overweight or obesity in the U.S. have a one in 10 annual probability of achieving a 5% or greater weight loss, and the likelihood for weight loss increases with a higher initial BMI, according to study data.

In response to safety concerns surrounding sedation for patients prescribed glucagon-like peptide-1 receptor agonists, the AGA, AASLD, ACG, ASGE and NASPGHAN encourage gastroenterologists to follow “best practices” for endoscopy procedures.

Two different trials showed that adults with obesity lost an average of 26% of their body weight with either intensive lifestyle intervention followed by 72 weeks of Mounjaro or 88 weeks of continuous Mounjaro use.

BOSTON — Intermittent fasting was associated with weight loss and improved markers of glycemic control and anthropometric measures in adults with type 2 diabetes or prediabetes and overweight or obesity, data presented at NUTRITION showed.

Adults with obesity who used tirzepatide for 72 weeks after lifestyle intervention or continuously for 88 weeks achieved a mean weight loss of 26%, according to topline results from two SURMOUNT trials.